RESUMO
Magnesium (Mg)-based biomaterials hold considerable promise for applications in regenerative medicine. However, the degradation of Mg needs to be reduced to control toxicity caused by its rapid natural corrosion. In the process of developing new Mg alloys with various surface modifications, an efficient assessment of the relevant properties is essential. In the present study, a WE43 Mg alloy with a plasma electrolytic oxidation (PEO)-generated surface was investigated. Surface microstructure, hydrogen gas evolution in immersion tests and cytocompatibility were assessed. In addition, a novel in vitro immunological test using primary human lymphocytes was introduced. On PEO-treated WE43, a larger number of pores and microcracks, as well as increased roughness, were observed compared to untreated WE43. Hydrogen gas evolution after two weeks was reduced by 40.7% through PEO treatment, indicating a significantly reduced corrosion rate. In contrast to untreated WE43, PEO-treated WE43 exhibited excellent cytocompatibility. After incubation for three days, untreated WE43 killed over 90% of lymphocytes while more than 80% of the cells were still vital after incubation with the PEO-treated WE43. PEO-treated WE43 slightly stimulated the activation, proliferation and toxin (perforin and granzyme B) expression of CD8+ T cells. This study demonstrates that the combined assessment of corrosion, cytocompatibility and immunological effects on primary human lymphocytes provide a comprehensive and effective procedure for characterizing Mg variants with tailorable degradation and other features. PEO-treated WE43 is a promising candidate for further development as a degradable biomaterial.
Assuntos
Materiais Revestidos Biocompatíveis , Magnésio/química , Teste de Materiais , Animais , Células Cultivadas , Materiais Revestidos Biocompatíveis/química , Materiais Revestidos Biocompatíveis/farmacocinética , Materiais Revestidos Biocompatíveis/farmacologia , Corrosão , Equipamentos e Provisões , Humanos , Sistema Imunitário/efeitos dos fármacos , Linfócitos/efeitos dos fármacos , Linfócitos/fisiologia , Magnésio/farmacocinética , Magnésio/farmacologia , Compostos de Magnésio/química , Compostos de Magnésio/farmacocinética , Compostos de Magnésio/farmacologia , Teste de Materiais/métodos , Camundongos , OxirreduçãoRESUMO
The Alginate-Neusilin US2 micro-composite (MC) beads were fabricated and optimized for oral delivery of hesperidin (HES). A 32 full factorial design encompassing independent variables (factors) such as the concentration of sodium alginate (X1), and Neusilin US2 (X2) and dependant variables (response) such as particle size (Y1), entrapment efficiency (Y2), and swelling degree (Y3). Nine batches were prepared by formulation design employing statistical software JMP 13.2.1. The multiple regression analysis (MLRA) was carried to explore the influence of factor over responses. Further, a prediction profiler was used to trace the optimum concentration of factors based on desirable responses. The optimized beads (OF) were characterized for their morphology and size by motic microscopy and scanning electron microscopy. In vitro release, kinetic studies were performed in simulated gastric and intestinal fluids. In vivo pharmacokinetic studies revealed better absorption of HES from optimized beads (OF) compared to HES suspension which could be due to the prevention of acidic degradation of HES in the stomach. The estimated shelf life of OF formulation was found to be 3.86 years suggested better stability after fabrication. In a nutshell, the developed micro-composite beads of HES could be a better alternative for promising oral sustained delivery of HES.
Assuntos
Alginatos/química , Compostos de Alumínio/química , Portadores de Fármacos/química , Suco Gástrico/metabolismo , Hesperidina/administração & dosagem , Compostos de Magnésio/química , Silicatos/química , Administração Oral , Alginatos/administração & dosagem , Alginatos/farmacocinética , Compostos de Alumínio/administração & dosagem , Compostos de Alumínio/farmacocinética , Animais , Líquidos Corporais/metabolismo , Técnicas de Química Analítica , Portadores de Fármacos/administração & dosagem , Portadores de Fármacos/farmacocinética , Composição de Medicamentos , Liberação Controlada de Fármacos , Estabilidade de Medicamentos , Hesperidina/farmacocinética , Intestinos , Cinética , Compostos de Magnésio/administração & dosagem , Compostos de Magnésio/farmacocinética , Masculino , Microscopia Eletrônica de Varredura , Microesferas , Tamanho da Partícula , Ratos Wistar , Silicatos/administração & dosagem , Silicatos/farmacocinéticaRESUMO
AIM: Canagliflozin (CFZ), a novel SGLT II antagonist, exhibits erratic absorption after oral administration. The current study entails development and evaluation of spray dried lipid based formulation (solid SMEDDS) for enhancing oral bioavailability and anti-diabetic activity of CFZ. METHODS: Solid SMEDDS developed through spray drying containing Neusilin US2 as an adsorbent. The formed solid SMEDDS were characterized for physicochemical and solid state attributes. Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM) were used to confirm the spherical morphology. In vitro dissolution, ex vivo permeability and in vivo pharmacokinetic studies were conducted to determine the release rate, permeation rate and absorption profile of CFZ, respectively. Pharmacodynamic studies were done as per standard protocols. RESULTS: The optimized solid SMEDDS exhibited acceptable practical yield and flow properties and is vouched with enhanced amorphization, nanoparticulate distribution and acceptable drug content. The spherical morphology of solid SMEDDS and reconstituted SMEDDS were confirmed in SEM and TEM, respectively. In vitro dissolution studies revealed multi-fold release behavior in CFZ in various dissolution media, whereas, remarkable permeability was observed in jejunum segment of rat intestine. Pharmacokinetic studies of CFZ in solid SMEDDS demonstrated 2.53 and 1.43 fold enhancement in Cmax and 2.73 and 1.98 fold in AUC 0-24h, as compared to pure API and marketed formulation, respectively. Pharmacological evaluation of solid SMEDDS revealed enhanced anti-diabetic activity of CFZ through predominant SGLT II inhibition in rats, as evident from evaluation of biochemical levels, urinary glucose excretion studies and SGLT II expression analysis. CONCLUSION: The current work describes significant improvement biopharmaceutical properties of CFZ in solid SMEDD formulation. Graphical abstract Graphical Abstract: Enhanced oral bioavailability and anti-diabetic activity of canagliflozin through a spray dried lipid based oral delivery: a novel paradigm.
Assuntos
Canagliflozina/administração & dosagem , Diabetes Mellitus Experimental/tratamento farmacológico , Sistemas de Liberação de Medicamentos , Hipoglicemiantes/administração & dosagem , Administração Oral , Compostos de Alumínio/administração & dosagem , Compostos de Alumínio/química , Compostos de Alumínio/farmacocinética , Animais , Disponibilidade Biológica , Canagliflozina/sangue , Canagliflozina/química , Canagliflozina/farmacocinética , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/urina , Liberação Controlada de Fármacos , Glicosúria , Hipoglicemiantes/sangue , Hipoglicemiantes/química , Hipoglicemiantes/farmacocinética , Absorção Intestinal , Rim/efeitos dos fármacos , Rim/metabolismo , Lipídeos/administração & dosagem , Lipídeos/química , Lipídeos/farmacocinética , Compostos de Magnésio/administração & dosagem , Compostos de Magnésio/química , Compostos de Magnésio/farmacocinética , Excipientes Farmacêuticos/administração & dosagem , Excipientes Farmacêuticos/química , Excipientes Farmacêuticos/farmacocinética , Ratos Wistar , Silicatos/administração & dosagem , Silicatos/química , Silicatos/farmacocinética , Transportador 2 de Glucose-Sódio/metabolismo , Secagem por AtomizaçãoRESUMO
The toxicity of arsenic in drinking water is hazardous for human health. Different strategies are used for arsenic removal from drinking water. Nanoparticles with higher adsorption capacities are useful for arsenic remediation. In the current study, magnesium ferrite nanoparticles were synthesised by three different methods followed by their characterisation XRD, SEM, and EDX. The SEM morphology and the porosity of magnesium ferrite nanoparticles were best in case of auto-combustion method. These particles had an average particle size of about 20-50â nm with spherical shape. These particles showed efficient remediation of arsenic up to 96% within 0.5â h. However, the co-precipitation and sol-gel-based nanoparticles showed arsenic remediation upto85 and 87% at 0.5-h time point. Moreover, the minimum inhibitory concentration of nanoparticles against two strains E.coli and Pseudomonas aeruginosa was found to be4.0â mg/L of these nanoparticles. However, the sol-gel-based nanoparticles showed efficient anti-microbial activity against E.coli at 4.0 and 8.0â mg/L against Pseudomonas aeruginosa. The co-precipitation-based nanoparticles were least efficient both for arsenic remediation and anti-microbial purposes. Thus, the synthesised auto-combustion-based nanoparticles are multifunctional in nature.
Assuntos
Anti-Infecciosos/síntese química , Compostos Férricos/síntese química , Compostos de Magnésio/síntese química , Nanopartículas/química , Nanotecnologia/métodos , Purificação da Água , Adsorção , Anti-Infecciosos/química , Anti-Infecciosos/farmacologia , Arsênio/isolamento & purificação , Arsênio/farmacocinética , Recuperação e Remediação Ambiental/métodos , Escherichia coli/efeitos dos fármacos , Escherichia coli/crescimento & desenvolvimento , Compostos Férricos/química , Compostos Férricos/farmacocinética , Humanos , Compostos de Magnésio/química , Compostos de Magnésio/farmacocinética , Teste de Materiais , Testes de Sensibilidade Microbiana , Pseudomonas aeruginosa/efeitos dos fármacos , Pseudomonas aeruginosa/crescimento & desenvolvimento , Poluentes Químicos da Água/isolamento & purificação , Poluentes Químicos da Água/farmacocinética , Purificação da Água/instrumentação , Purificação da Água/métodos , Difração de Raios XRESUMO
The blood-brain barrier (BBB) tightly regulates the homeostasis of the central nervous system, and its dysfunction has been described in several neurological disorders. Since magnesium exerts a protective effect in the brain, we assessed whether supraphysiological concentrations of different magnesium salts modulate the permeability and magnesium transport in in vitro models of rat and human BBB. Among various formulations tested, magnesium pidolate was the most efficient in reducing the permeability and in enhancing magnesium transport through the barrier. We then compared magnesium pidolate and magnesium sulfate, a widely used salt in experimental models and in clinical practice. Magnesium pidolate performs better than sulfate also in preventing lipopolysaccharide-induced damage to in vitro generated BBB. We conclude that magnesium pidolate emerges as an interesting alternative to sulfate to protect BBB and maintain correct intracerebral concentrations of magnesium.
Assuntos
Barreira Hematoencefálica/efeitos dos fármacos , Permeabilidade Capilar/efeitos dos fármacos , Células Endoteliais/efeitos dos fármacos , Compostos de Magnésio/farmacocinética , Animais , Transporte Biológico , Barreira Hematoencefálica/metabolismo , Técnicas de Cultura de Células , Células Cultivadas , Células Endoteliais/metabolismo , Humanos , Compostos de Magnésio/química , Compostos de Magnésio/farmacologia , RatosRESUMO
Magnesium, one of the basic elements for the human body, is necessary for many physiological functions. Magnesium deficiency is widely observed as a result of the reduced nutrient content of foods, over-cooking, diseases, drugs, alcohol, and caffeine consumption. Taking a dietary supplement is necessary magnesium deficiency. It has been demonstrated that absorption of organic magnesium compounds is better than absorption of inorganic compounds. The aim of this study is to investigate transitions to tissues of different organic magnesium compounds in different doses and whether there is a difference in the organic acid-bounded compounds (magnesium citrate and magnesium malate) and the amino acid-bounded compounds (magnesium acetyl taurate and magnesium glycinate), associated with transition and bioavailability. In addition, the effects of split dosages of high doses in a high volume of solvent on tissue magnesium levels are being investigated, because galenic formulation problems are regarded to prepare convenient dosage that can be taken once a day. All magnesium compounds were administered as three different doses, 45, 135, and 405 mg/70 kg elemental magnesium, were given per orally to Balbc mice. In a second set of experiments, 405 mg/70 kg high dose was divided into two doses of 202.5 mg/70 kg each and administered every 12 h. Brain, muscle tissues, and serum magnesium levels measured in all experimental groups and control 24 h later. Brain magnesium levels were found increased in all magnesium acetyl taurate administered subjects. Magnesium citrate increased muscle and brain magnesium levels in a dose-independent manner. We showed that dividing high doses of daily administered magnesium compounds did not sufficiently increase tissue magnesium levels. Although passive paracellular mechanism by solvent drag is the main mechanism of Mg absorption, other factors (electrochemical gradient effects, transcellular transporter mechanisms, magnesium status) should be effective on our results. It is necessary for further research on long-term administration of different magnesium compounds and their effect on other tissues.
Assuntos
Compostos de Magnésio/farmacocinética , Administração Oral , Animais , Disponibilidade Biológica , Relação Dose-Resposta a Droga , Compostos de Magnésio/administração & dosagem , Camundongos , Camundongos Endogâmicos BALB C , Distribuição TecidualRESUMO
Magnesium is an element of great importance functioning because of its association with many cellular physiological functions. The magnesium content of foods is gradually decreasing due to food processing, and magnesium supplementation for healthy living has become increasingly popular. However, data is very limited on the bioavailability of various magnesium preparations. The aim of this study is to investigate the bioavailability of five different magnesium compounds (magnesium sulfate, magnesium oxide, magnesium acetyl taurate, magnesium citrate, and magnesium malate) in different tissues. Following a single dose 400 mg/70 kg magnesium administration to Sprague Dawley rats, bioavailability was evaluated by examining time-dependent absorption, tissue penetration, and the effects on the behavior of the animals. Pharmacokinetically, the area under the curve calculation is highest in the magnesium malate. The magnesium acetyl taurate was found to have the second highest area under the curve calculation. Magnesium acetyl taurate was rapidly absorbed, able to pass through to the brain easily, had the highest tissue concentration level in the brain, and was found to be associated with decreased anxiety indicators. Magnesium malate levels remained high for an extended period of time in the serum. The commonly prescribed dietary supplements magnesium oxide and magnesium citrate had the lowest bioavailability when compared to our control group. More research is needed to investigate the bioavailability of magnesium malate and acetyl taurate compounds and their effects in specific tissues and on behavior.
Assuntos
Compostos de Magnésio/metabolismo , Compostos de Magnésio/farmacocinética , Animais , Área Sob a Curva , Disponibilidade Biológica , Suplementos Nutricionais , Compostos de Magnésio/administração & dosagem , Masculino , Ratos , Ratos Sprague-Dawley , Fatores de TempoRESUMO
A novel aluminum/olivine composite (AOC) was prepared by wet impregnation followed by calcination and was introduced as an efficient adsorbent for defluoridation. The adsorption of fluoride was modeled with one-, two- and three-parameter isotherm equations by non-linear regression to demonstrate the adsorption equilibrium. The FI was the best-fitted model among the two-parameter isotherms with a R2 value of 0.995. The three-parameter models were found to have better performance with low values of the error functions and high F values. The neural-network-based model was applied for the first time in the isotherm study. The optimized model was framed with eight neurons in hidden layer with a mean square of error of 0.0481 and correlation coefficient greater than 0.999. The neural-based model has the better predictability with a higher F value of 9484 and R2 value of 0.998 compared to regression models, exhibiting the F value and the R2 in the range of 86-3572 and 0.835-0.995, respectively. The material characterization established the formation of the aluminum oxide, silicate, etc. onto the olivine which is conducive of the removal of fluoride by the formation of aluminum fluoride compounds, such as AlF3 in the spent material after defluoridation.
Assuntos
Fluoretos/farmacocinética , Compostos de Ferro/farmacocinética , Compostos de Magnésio/farmacocinética , Redes Neurais de Computação , Silicatos/farmacocinética , Purificação da Água , Absorção Fisico-Química , Alumínio/química , Alumínio/farmacocinética , Óxido de Alumínio/química , Fenômenos Químicos , Fluoretos/química , Compostos de Ferro/química , Cinética , Análise dos Mínimos Quadrados , Compostos de Magnésio/química , Silicatos/química , Temperatura , Purificação da Água/instrumentação , Purificação da Água/métodosRESUMO
Magnesium phosphate minerals have captured increasing attention during the past years as suitable alternatives for calcium phosphate bone replacement materials. Here, we investigated the degradation and bone regeneration capacity of experimental struvite (MgNH4PO4·6H2O) forming magnesium phosphate cements in two different orthotopic ovine implantation models. Cements formed at powder to liquid ratios (PLR) of 2.0 and 3.0â¯gâ¯ml-1 were implanted into trabecular bone using a non-load-bearing femoral drill-hole model and a load-bearing tibial defect model. After 4, 7 and 10â¯months the implants were retrieved and cement degradation and new bone formation was analyzed by micro-computed tomography (µCT) and histomorphometry. The results showed cement degradation in concert with new bone formation at both defect locations. Both cements were almost completely degraded after 10â¯months. The struvite cement formed with a PLR of 2.0â¯gâ¯ml-1 exhibited a slightly accelerated degradation kinetics compared to the cement with a PLR of 3.0â¯gâ¯ml-1. Tartrat-resistant acid phosphatase (TRAP) staining indicated osteoclastic resorption at the cement surface. Energy dispersive X-ray analysis (EDX) revealed that small residual cement particles were mostly accumulated in the bone marrow in between newly formed bone trabeculae. Mechanical loading did not significantly increase bone formation associated with cement degradation. Concluding, struvite-forming cements might be promising bone replacement materials due to their good degradation which is coupled with new bone formation. STATEMENT OF SIGNIFICANCE: Recently, the interest in magnesium phosphate cements (MPC) for bone substitution increased, as they exhibit high initial strength, comparably elevated degradation potential and the release of valuable magnesium ions. However, only few in vivo studies, mostly including non-load-bearing defects in small animals, have been performed to analyze the degradation and regeneration capability of MPC derived compounds. The present study examined the in vivo behavior of magnesiumammoniumphosphate hexahydrate (struvite) implants with different porosity in both mechanically loaded and non-loaded defects of merino sheep. For the first time, the effect of mechanical stimuli on the biological outcome of this clinically relevant replacement material is shown and directly compared to the conventional unloaded defect situation in a large animal model.
Assuntos
Cimentos Ósseos , Regeneração Óssea/efeitos dos fármacos , Osso Esponjoso , Fêmur , Compostos de Magnésio , Fosfatos , Animais , Cimentos Ósseos/química , Cimentos Ósseos/farmacocinética , Cimentos Ósseos/farmacologia , Osso Esponjoso/lesões , Osso Esponjoso/metabolismo , Osso Esponjoso/patologia , Modelos Animais de Doenças , Feminino , Fêmur/lesões , Fêmur/metabolismo , Fêmur/patologia , Compostos de Magnésio/química , Compostos de Magnésio/farmacocinética , Compostos de Magnésio/farmacologia , Fosfatos/química , Fosfatos/farmacocinética , Fosfatos/farmacologia , OvinosRESUMO
The risk of penetrating, traumatic injury occurring in a chemically contaminated environment cannot be discounted. Should a traumatic injury be contaminated with a chemical warfare (CW) agent, it is likely that standard haemostatic treatment options would be complicated by the need to decontaminate the wound milieu. Thus, there is a need to develop haemostatic products that can simultaneously arrest haemorrhage and decontaminate CW agents. The purpose of this study was to evaluate a number of candidate haemostats for efficacy as skin decontaminants against three CW agents (soman, VX and sulphur mustard) using an in vitro diffusion cell containing undamaged pig skin. One haemostatic product (WoundStat™) was shown to be as effective as the standard military decontaminants Fuller's earth and M291 for the decontamination of all three CW agents. The most effective haemostatic agents were powder-based and use fluid absorption as a mechanism of action to sequester CW agent (akin to the decontaminant Fuller's earth). The envisaged use of haemostatic decontaminants would be to decontaminate from within wounds and from damaged skin. Therefore, WoundStat™ should be subject to further evaluation using an in vitro model of damaged skin.
Assuntos
Substâncias para a Guerra Química/toxicidade , Descontaminação/métodos , Hemostáticos/farmacocinética , Ferimentos e Lesões/tratamento farmacológico , Compostos de Alumínio/farmacocinética , Animais , Compostos de Magnésio/farmacocinética , Gás de Mostarda/toxicidade , Compostos Organotiofosforados/toxicidade , Silicatos/farmacocinética , Pele/efeitos dos fármacos , Absorção Cutânea/efeitos dos fármacos , Soman/toxicidade , Suínos , Ferimentos e Lesões/induzido quimicamente , Ferimentos e Lesões/patologiaRESUMO
Magnesium phosphate compounds, as for example struvite (MgNH4PO4·6H2O), have comparable characteristics to calcium phosphate bone substitutes, but degrade faster under physiological conditions. In the present work, we used a struvite forming calcium doped magnesium phosphate cement with the formulation Ca0.75Mg2.25(PO4)2 and an ammonium phosphate containing aqueous solution to produce round-shaped granules. For the fabrication of spherical granules, the cement paste was dispersed in a lipophilic liquid and stabilized by surfactants. The granules were characterized with respect to morphology, size distribution, phase composition, compressive strength, biocompatibility and solubility. In general, it was seen that small granules can hardly be produced by means of emulsification, when the raw material is a hydraulic paste, because long setting times promote coalescence of initially small unhardened cement droplets. Here, this problem was solved by using an aqueous solution containing both the secondary (NH4)2HPO4 and primary ammonium phosphates NH4H2PO4 to accelerate the setting reaction. This resulted in granules with 97 wt.% having a size in the range between 200 and 1,000 µm. The novel solution composition doubled the compressive strength of the cement to 37 ± 5 MPa without affecting either the conversion to struvite or the cytocompatibility using human fetal osteoblasts.
Assuntos
Compostos de Magnésio/química , Microesferas , Fosfatos/química , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Força Compressiva , Emulsões , Humanos , Concentração de Íons de Hidrogênio , Compostos de Magnésio/farmacocinética , Compostos de Magnésio/toxicidade , Teste de Materiais , Tamanho da Partícula , Fosfatos/farmacocinética , Fosfatos/toxicidade , EstruvitaRESUMO
PURPOSE: To evaluate a new class of manganese porphyrins with tunable pharmacokinetics as potential gadolinium (Gd)-free T1 agents for contrast-enhanced magnetic resonance imaging (MRI). MATERIALS AND METHODS: Two new contrast agents, MnTCP and MnP2, were evaluated in four female rats. MRI was performed daily up to 3 days postinjection (0.05 mmol/kg) on a 3 T clinical scanner. T1 relaxation times and dynamic contrast-enhanced MRI were performed to assess contrast enhancement and clearance in blood, heart, liver, kidney, and muscle. RESULTS: Relative T1 decreases were similar for MnTCP and Gd-DTPA in all tissues but were significantly larger (P < 0.05) for MnP2 in blood, heart, kidney, and liver (2-6-fold larger). Clearance of MnTCP was similar to Gd-DTPA, with T1 returning to baseline by 40 minutes and complete elimination in 1 day. MnP2 was cleared from blood after 2 days and sustained a lowered T1 in other tissues for at least 1 hour (P < 0.05). The maximum enhancement, slope, and time-to-peak were similar between contrast agents. Only the parameter AUC60 differed, with MnP2 yielding the largest AUC60 values primarily through longer retention in tissue. CONCLUSION: MnTCP and MnP2 offer distinct applications as Gd-free T1 contrast agents. MnTCP behaves like a Gd-DTPA analog, while MnP2 provides significantly greater and longer positive signal enhancement.
Assuntos
Compostos de Magnésio/farmacocinética , Imageamento por Ressonância Magnética/métodos , Porfirinas/farmacocinética , Imagem Corporal Total/métodos , Animais , Meios de Contraste/farmacocinética , Feminino , Taxa de Depuração Metabólica , Especificidade de Órgãos/fisiologia , Ratos , Ratos Long-Evans , Distribuição TecidualRESUMO
The article examines the role of magnesium in the metabolism and the pathogenesis of common cardiovascular diseases, and provides research data on the use of magnesium salts as adjunctive therapy of these diseases.
Assuntos
Doenças Cardiovasculares/tratamento farmacológico , Hemodinâmica/efeitos dos fármacos , Compostos de Magnésio/uso terapêutico , Doenças Cardiovasculares/sangue , Humanos , Magnésio/sangue , Compostos de Magnésio/farmacocinética , Resultado do TratamentoRESUMO
Maximum contaminant levels are used to control potential health hazards posed by chemicals in drinking water, but no primary national or international limits for aluminum (Al) have been adopted. Given the differences in toxicological profiles, the present evaluation derives total allowable concentrations for certain water-soluble inorganic Al compounds (including chloride, hydroxide, oxide, phosphate and sulfate) and for the hydrated Al silicates (including attapulgite, bentonite/montmorillonite, illite, kaolinite) in drinking water. The chemistry, toxicology and clinical experience with Al materials are extensive and depend upon the particular physical and chemical form. In general, the water solubility of the monomeric Al materials depends on pH and their water solubility and gastrointestinal bioavailability are much greater than that of the hydrated Al silicates. Other than Al-containing antacids and buffered aspirin, food is the primary source of Al exposure for most healthy people. Systemic uptake of Al after ingestion of the monomeric salts is somewhat greater from drinking water (0.28%) than from food (0.1%). Once absorbed, Al accumulates in bone, brain, liver and kidney, with bone as the major site for Al deposition in humans. Oral Al hydroxide is used routinely to bind phosphate salts in the gut to control hyperphosphatemia in people with compromised renal function. Signs of chronic Al toxicity in the musculoskeletal system include a vitamin D-resistant osteomalacia (deranged membranous bone formation characterized by accumulation of the osteoid matrix and reduced mineralization, reduced numbers of osteoblasts and osteoclasts, decreased lamellar and osteoid bands with elevated Al concentrations) presenting as bone pain and proximal myopathy. Aluminum-induced bone disease can progress to stress fractures of the ribs, femur, vertebrae, humerus and metatarsals. Serum Al ≥100 µg/L has a 75-88% positive predictive value for Al bone disease. Chronic Al toxicity is also manifest in the hematopoietic system as an erythropoietin-resistant microcytic hypochromic anemia. Signs of Al toxicity in the central nervous system (speech difficulty to total mutism to facial grimacing to multifacial seizures and dyspraxia) are related to Al accumulation in the brain and these symptoms can progress to frank encephalopathy. There are four groups of people at elevated risk of systemic Al intoxication after repeated ingestion of monomeric Al salts: the preterm infant, the infant with congenital uremia and children and adults with kidney disease. There is a dose-dependent increase in serum and urinary Al in people with compromised renal function, and restoration of renal function permits normal handling of systemically absorbed Al and resolution of Al bone disease. Clinical experience with 960 mg/day of Al(OH)(3) (~5 mg Al/kg-day) given by mouth over 3 months to men and women with compromised renal function found subclinical reductions in hemoglobin, hematocrit and serum ferritin. Following adult males and females with reduced kidney function found that ingestion of Al(OH)(3) at 2.85 g/day (~40 mg/kg-day Al) over 7 years increased bone Al, but failed to elicit significant bone toxicity. There was one report of DNA damage in cultured lymphocytes after high AlCl(3) exposure, but there is no evidence that ingestion of common inorganic Al compounds presents an increased carcinogenic risk or increases the risk for adverse reproductive or developmental outcomes. A number of studies of Al exposure in relation to memory in rodents have been published, but the results are inconsistent. At present, there is no evidence to substantiate the hypothesis that the pathogenesis of Alzheimer's Disease is caused by Al found in food and drinking water at the levels consumed by people living in North America and Western Europe. Attapulgite (palygorskite) has been used for decades at oral doses (recommended not to exceed two consecutive days) of 2,100 mg/day in children of 3-6 years, 4,200 mg/day in children of 6-12 years, and 9,000 mg/day in adults. Chronic ingestion of insoluble hydrated Al silicates (in kg) can result in disturbances in iron and potassium status, primarily as a result of clay binding to intestinal contents and enhanced fecal iron and zinc elimination. Sufficiently high doses of ingested Al silicates (≥50 g/day) over prolonged periods of time can elicit a deficiency anemia that can be corrected with oral Fe supplements. There is essentially no systemic Al uptake after ingestion of the hydrated Al silicates. Rats fed up to 20,000 ppm Ca montmorillonite (equivalent to 1,860 ppm total Al as the hydrated Al silicate) for 28 weeks failed to develop any adverse signs. The results of dietary Phase I and II clinical trials conducted in healthy adult volunteers over 14 days and 90 days with montmorillonite found no adverse effects after feeding up to 40 mg/kg-day as Al. Since the Al associated with ingestion of hydrated Al silicates is not absorbed into the systemic circulation, the hydrated Al silicates seldom cause medical problems unless the daily doses consumed are substantially greater than those used clinically or as dietary supplements. A no-observable-adverse-effect-level (NOAEL) of 13 mg/kg-day as total Al can be identified based on histologic osteomalacia seen in adult hemodialysis patients given Al hydroxide for up to 7 years as a phosphate binder. Following U.S. EPA methods for calculation of an oral reference dose (RfD), an intraspecies uncertainty factor of 10x was applied to that value results in a chronic oral reference dose (RfD) of 1.3 mg Al/kg-day; assuming a 70-kg adult consumes 2 L of drinking water per day and adjusting for a default 20% relative source contribution that value corresponds to a drinking water maximum concentration of 9 mg/L measured as total Al. A chronic NOAEL for montmorillonite as representative of the hydrated Al silicates was identified from the highest dietary concentration (20,000 ppm) fed in a 28-week bioassay with male and female Sprague-Dawley rats. Since young rats consume standard laboratory chow at ~23 g/day, this concentration corresponds to 56 mg Al/kg-day. Application of 3x interspecies uncertainty factor and a 3x factor to account for study duration results in a chronic oral RfD of 6 mg Al/kg-day. Of note, this RfD is 5-10 fold less than oral doses of Al silicates consumed by people who practice clay geophagy and it corresponds to a maximum drinking water concentration of 40 mg Al/L. To utilize the values derived here, the risk manager must recognize the particular product (e.g., alum) or source (e.g., groundwater, river water, clay or cement pipe) of the Al found in tap water, apply the appropriate analytical methods (atomic absorption, energy dispersive X-ray diffraction, infrared spectral analysis and/or scanning transmission electron microscopy) and compare the results to the most relevant standard. The drinking water concentrations derived here are greater than the U.S. EPA secondary maximum contaminant level (MCL) for total Al of 0.05-0.2 mg/L [40 CFR 143.3]. As such, domestic use of water with these concentrations is likely self-limiting given that its cloudy appearance will be greater than the maximum permitted (0.5-5.0 nephalometric turbidity units; 40 CFR Parts 141 and 142). Therefore, the organoleptic properties of Al materials in water determine public acceptance of potable water as contrast to any potential health hazard at the concentrations ordinarily present in municipal drinking water.
Assuntos
Compostos de Alumínio/análise , Silicatos de Alumínio/análise , Exposição Ambiental , Monitoramento Ambiental/métodos , Compostos de Magnésio/análise , Silicatos/análise , Poluentes Químicos da Água/análise , Abastecimento de Água/análise , Adulto , Compostos de Alumínio/farmacocinética , Compostos de Alumínio/toxicidade , Silicatos de Alumínio/farmacocinética , Silicatos de Alumínio/toxicidade , Animais , Disponibilidade Biológica , Criança , Pré-Escolar , Relação Dose-Resposta a Droga , Feminino , Humanos , Compostos de Magnésio/farmacocinética , Compostos de Magnésio/toxicidade , Masculino , Concentração Máxima Permitida , Ratos , Silicatos/farmacocinética , Silicatos/toxicidade , Testes de Toxicidade , Poluentes Químicos da Água/farmacocinética , Poluentes Químicos da Água/toxicidade , Abastecimento de Água/normasRESUMO
The ability of bacteria to colonize catheters is a major cause of infection. In the current study, catheters were surface-modified with MgF(2) nanoparticles (NPs) using a sonochemical synthesis protocol described previously. The one-step synthesis and coating procedure yielded a homogenous MgF(2) NP layer on both the inside and outside of the catheter, as analyzed by high resolution scanning electron microscopy and energy dispersive spectroscopy. The coating thickness varied from approximately 750 nm to 1000 nm on the inner walls and from approximately 450 nm to approximately 580 nm for the outer wall. The coating consisted of spherical MgF(2) NPs with an average diameter of approximately 25 nm. These MgF(2) NP-modified catheters were investigated for their ability to restrict bacterial biofilm formation. Two bacterial strains most commonly associated with catheter infections, Escherichia coli and Staphylococcus aureus, were cultured in tryptic soy broth, artificial urine and human plasma on the modified catheters. The MgF(2) NP-coated catheters were able to significantly reduce bacterial colonization for a period of 1 week compared to the uncoated control. Finally, the potential cytotoxicity of MgF(2) NPs was also evaluated using human and mammalian cell lines and no significant reduction in the mitochondrial metabolism was observed. Taken together, our results indicate that the surface modification of catheters with MgF(2) NPs can be effective in preventing bacterial colonization and can provide catheters with long-lasting self-sterilizing properties.
Assuntos
Antibacterianos/farmacologia , Biofilmes/efeitos dos fármacos , Cateteres de Demora , Fluoretos/farmacologia , Compostos de Magnésio/farmacologia , Nanopartículas/química , Animais , Antibacterianos/química , Antibacterianos/farmacocinética , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Estabilidade de Medicamentos , Escherichia coli/efeitos dos fármacos , Fluoretos/química , Fluoretos/farmacocinética , Células HEK293 , Células HeLa , Humanos , Compostos de Magnésio/química , Compostos de Magnésio/farmacocinética , Teste de Materiais , Sonicação , Staphylococcus aureus/efeitos dos fármacos , Propriedades de SuperfícieRESUMO
Nicotine (NCT) buccal tablets consisting of sodium alginate (SA) and nicotine-magnesium aluminum silicate (NCT-MAS) complexes acting as drug carriers were prepared using the direct compression method. The effects of the preparation pH levels of the NCT-MAS complexes and the complex/SA ratios on NCT release, permeation across mucosa, and mucoadhesive properties of the tablets were investigated. The NCT-MAS complex-loaded SA tablets had good physical properties and zero-order release kinetics of NCT, which indicate a swelling/erosion-controlled release mechanism. Measurement of unidirectional NCT release and permeation across porcine esophageal mucosa using a modified USP dissolution apparatus 2 showed that NCT delivery was controlled by the swollen gel matrix of the tablets. This matrix, which controlled drug diffusion, resulted from the molecular interactions of SA and MAS. Tablets containing the NCT-MAS complexes prepared at pH 9 showed remarkably higher NCT permeation rates than those containing the complexes prepared at acidic and neutral pH levels. Larger amounts of SA in the tablets decreased NCT release and permeation rates. Additionally, the presence of SA could enhance the mucoadhesive properties of the tablets. These findings suggest that SA plays the important role not only in controlling release and permeation of NCT but also for enhancing the mucoadhesive properties of the NCT-MAS complex-loaded SA tablets, and these tablets demonstrate a promising buccal delivery system for NCT.
Assuntos
Alginatos/síntese química , Compostos de Alumínio/síntese química , Portadores de Fármacos/síntese química , Compostos de Magnésio/síntese química , Nicotina/síntese química , Silicatos/síntese química , Administração Bucal , Alginatos/administração & dosagem , Alginatos/farmacocinética , Compostos de Alumínio/administração & dosagem , Compostos de Alumínio/farmacocinética , Animais , Portadores de Fármacos/administração & dosagem , Portadores de Fármacos/farmacocinética , Sistemas de Liberação de Medicamentos/métodos , Sistemas de Liberação de Medicamentos/normas , Ácido Glucurônico/administração & dosagem , Ácido Glucurônico/síntese química , Ácido Glucurônico/farmacocinética , Ácidos Hexurônicos/administração & dosagem , Ácidos Hexurônicos/síntese química , Ácidos Hexurônicos/farmacocinética , Concentração de Íons de Hidrogênio , Compostos de Magnésio/administração & dosagem , Compostos de Magnésio/farmacocinética , Mucosa Bucal/efeitos dos fármacos , Mucosa Bucal/metabolismo , Nicotina/administração & dosagem , Nicotina/farmacocinética , Silicatos/administração & dosagem , Silicatos/farmacocinética , Suínos , ComprimidosRESUMO
OBJECT: Disturbance of cerebral phosphorus-containing metabolites occurs in many disease entities and has not been widely studied in patients with subarachnoid hemorrhage (SAH). Pilot studies have indicated that hypermagnesemic treatment may improve outcome in patients with aneurysmal SAH, but the precise mechanism is not known. The authors hypothesized that, by raising intracellular brain free magnesium in aneurysmal SAH, hypermagnesemic treatment would alter the cerebral energy status. METHODS: The authors designed the current study to use ³¹P-MR spectroscopy (MRS) to investigate intracellular brain free magnesium and cerebral phosphorus-containing metabolites in patients with good-grade aneurysmal SAH, both those receiving and not receiving hypermagnesemic therapy. A total of 37 eligible patients and 23 healthy volunteers were recruited. A total of 81 MRS studies were performed. RESULTS: Hypermagnesemic treatment after aneurysmal SAH produced a small (mean difference 0.018 ± 0.007 mM [+ 13.0%]) but significant elevation of intracellular free magnesium during the 1st week. Aneurysmal SAH produced a depressed membrane metabolism with lower phosphodiester/total phosphate. CONCLUSIONS: The MRS finding of elevated brain free intracellular magnesium after intravenous magnesium sulfate infusion is novel, and the changes in membrane metabolism provide insight into the metabolic effects of aneurysmal SAH and future pathophysiological studies.
Assuntos
Química Encefálica/efeitos dos fármacos , Compostos de Magnésio/uso terapêutico , Magnésio/metabolismo , Fósforo/metabolismo , Hemorragia Subaracnóidea/metabolismo , Hemorragia Subaracnóidea/terapia , Adulto , Idoso , Isquemia Encefálica/complicações , Coma/etiologia , Metabolismo Energético/efeitos dos fármacos , Feminino , Escala de Coma de Glasgow , Humanos , Magnésio/sangue , Compostos de Magnésio/farmacocinética , Imageamento por Ressonância Magnética , Espectroscopia de Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Isótopos de FósforoRESUMO
We studied the effects of oral magnesium (Mg) salts either alone or in combination with pyridoxine hydrochloride in rats on pyridoxine-deficient diet. Fifty-four male rats were randomized into two groups and were fed either a standard diet or a pyridoxine-deficient diet for 3 weeks. A significant rise of the EGOT index ( > 1.5), oxaluria (from 74.8 +/- 5.2 to 117.9 +/- 12.3 mcM/l, p = 0.035), and crystalluria in rats fed with pyridoxine deficient diet were revealed. Oral Mg chloride, Mg L-aspartate either alone or in combination with pyridoxine in comparison with magnesium sulfate, magne B6 (Mg lactate with pyridoxine) and pyridoxine alone were administered (50 mg of magnesium and/or 5 mg of pyridoxine per kg body weight). Magnesium salts in combination with pyridoxine lowered an oxalate level and crystalluria whereas magnesium salts alone reduced only crystalluria. Antilithis effects of Mg L-aspartate and Mg chloride in combination with pyridoxine were comparable with those observed in magne B6 or pyridoxine treatment and were significantly higher than in magnesium sulfate treatment.
Assuntos
Dieta , Hiperoxalúria/prevenção & controle , Compostos de Magnésio/uso terapêutico , Oxalatos/urina , Piridoxina/uso terapêutico , Animais , Aspartato Aminotransferases/metabolismo , Ácido Aspártico/administração & dosagem , Ácido Aspártico/farmacocinética , Ácido Aspártico/uso terapêutico , Cristalização , Modelos Animais de Doenças , Quimioterapia Combinada , Eritrócitos/enzimologia , Hiperoxalúria/sangue , Hiperoxalúria/etiologia , Hiperoxalúria/urina , Magnésio/sangue , Magnésio/urina , Cloreto de Magnésio/administração & dosagem , Cloreto de Magnésio/farmacocinética , Cloreto de Magnésio/uso terapêutico , Compostos de Magnésio/administração & dosagem , Compostos de Magnésio/farmacocinética , Sulfato de Magnésio/administração & dosagem , Sulfato de Magnésio/farmacocinética , Sulfato de Magnésio/uso terapêutico , Masculino , Piridoxina/administração & dosagem , Piridoxina/deficiência , Ratos , Resultado do TratamentoRESUMO
The authors summarize the role of essential macro metal elements (Na, K, Ca, Mg) in human body: their homeostasis, absorption, transport, storage and excretion. Metabolism of macro-elements, daily requirements, cause of metal deficiencies and diseases caused by deficiencies are also discussed. Messenger and prooxidant effect of Ca2+-ions, indirect antioxidant effect of Mg2+-ions and the adjuvant application of magnesium are also reviewed.
Assuntos
Cálcio da Dieta/farmacocinética , Deficiências Nutricionais/metabolismo , Canais Iônicos/metabolismo , Compostos de Magnésio/farmacocinética , Potássio na Dieta/farmacocinética , Sódio na Dieta/farmacocinética , Antioxidantes/farmacocinética , Transporte Biológico Ativo , Cálcio/deficiência , Canais de Cálcio/metabolismo , Cálcio da Dieta/administração & dosagem , Cálcio da Dieta/metabolismo , Deficiências Nutricionais/diagnóstico , Humanos , Absorção Intestinal , Transporte de Íons/fisiologia , Compostos de Magnésio/administração & dosagem , Compostos de Magnésio/metabolismo , Deficiência de Magnésio/metabolismo , Oxidantes/farmacocinética , Canais de Potássio/metabolismo , Deficiência de Potássio/metabolismo , Potássio na Dieta/administração & dosagem , Potássio na Dieta/metabolismo , Sódio/deficiência , Canais de Sódio/metabolismo , Sódio na Dieta/administração & dosagem , Sódio na Dieta/metabolismoRESUMO
Diclofenac calcium-alginate (DCA) beads were reinforced with different amounts of sodium starch glycolate (SSG) or magnesium aluminum silicate (MAS) and were prepared using ionotropic gelation method. Complex formation of sodium alginate (SA) and SSG or MAS in calcium-alginate beads was revealed using FTIR spectroscopy. Differential scanning calorimetric study indicated that diclofenac sodium (DS) in amorphous form was dispersed in the matrix of DCA beads. The thermal behavior of SSG-DCA and MAS-DCA beads was similar to the control bead. Both additives can improve the entrapment efficiency of DCA beads. The swelling and water uptake of the beads depended on the properties of incorporated additives. The SSG-DCA beads showed a higher water uptake and swelling than MAS-DCA beads. Moreover, the swelling of the beads showed a good correlation with the square root of time. The release kinetic of the beads in pH 6.8 phosphate buffer was swelling controlled mechanism, while that in distilled water followed Higuchi's model. The slower release rate and the longer lag time in pH 6.8 phosphate buffer was obtained from the SSG-DCA and MAS-DCA beads because of complex formation between SA and SSG or MAS. However, SSG in the beads could increase the release of DS from the beads in distilled water because it acted as a channeling agent. In contrast, MAS retarded the release of DS from the beads in distilled water due to the stronger matrix formation.